BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 17686051)

  • 1. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
    Harrison SJ; Cook G; Nibbs RJ; Prince HM
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune regulation in multiple myeloma: the host-tumour conflict.
    Cook G; Campbell JD
    Blood Rev; 1999 Sep; 13(3):151-62. PubMed ID: 10527267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
    Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
    Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-based immunotherapy for multiple myeloma: current approaches.
    Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
    Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.
    Bogen B; Ruffini PA; Corthay A; Fredriksen AB; Frøyland M; Lundin K; Røsjø E; Thompson K; Massaia M
    Haematologica; 2006 Jul; 91(7):941-8. PubMed ID: 16818282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A;
    J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).
    Feyler S; Selby PJ; Cook G
    Blood Rev; 2013 May; 27(3):155-64. PubMed ID: 23623928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunotherapy of multiple myeloma: perspectives and perplexities.
    Di Bernardo A; Macor P; Guarnotta C; Franco G; Florena AM; Tedesco F; Tripodo C
    Expert Opin Biol Ther; 2010 Jun; 10(6):863-73. PubMed ID: 20367529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current role of immunotherapy in multiple myeloma.
    Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
    Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma, a model for fundamental and clinical research.
    Vande Broek I; Asosingh K; Vanderkerken K; Van Riet I; Van Camp B
    Verh K Acad Geneeskd Belg; 2002; 64(4):261-84; discussion 284-6. PubMed ID: 12416235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
    Chiriva-Internati M; Cobos E; Kast WM
    Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: diagnosis and treatment.
    Nau KC; Lewis WD
    Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunoglobulin substitution in malignant lymphoma].
    Wehmeier A
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():73-6; discussion 77. PubMed ID: 8499755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.